Key result
Higher admission cystatin C levels linked to adverse cardiovascular events at 6 months.
Why the study?
The relationship between plasma cystatin C concentration and acute coronary syndrome, as well as its prognostic significance, was not fully established.
Does plasma cystatin C concentration predict adverse cardiovascular events in patients with coronary artery disease?
Observational (n=160)
Does plasma cystatin C concentration predict adverse cardiovascular events in patients with coronary artery disease?
p-value: p=<0.01
Elevated plasma cystatin C levels are associated with acute coronary syndrome severity and predict adverse cardiovascular events at 6 months.
May aid risk stratification in CAD; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: This article aims to investigate the changes of plasma cystatin C concentration (PcyC), and to evaluate the relationship between PcyC and acute coronary syndrome. METHODS: A total of 126 consecutive patients with coronary artery disease (CAD) were enrolled in this study, consisting of 34 patients with stable angina pectoris (SAP), 56 patients with unstable angina pectoris (UAP), 36 patients with acute myocardial infarction (AMI), and 34 healthy subjects as controls. Plasma cystatin C, high sensitivity C-reactive protein (hs-CRP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and uric acid (UA) in all subjects were determined. All patients were followed up for 6 months and adverse cardiovascular events were recorded. RESULTS: Plasma cystatin C was elevated in CAD. Cystatin C levels were significantly higher in UAP patients than those in SAP patients and controls (2013.83 +/- 633.85 ng/mL vs 1348.41 +/- 369.62 ng/mL and 1509.99 +/- 408.65 ng/mL, P < 0.05), but were much lower than those in AMI patients (2013.83 +/- 633.85 ng/mL vs 2873.55 +/- 1149.48 ng/mL, P < 0.05). Patients with AMI also exhibited significantly higher cystatin C levels than SAP patients and the control group (2873.55 +/- 1149.48 ng/mL vs 1348.41 +/- 369.62 ng/mL and 1509.99 +/- 408.65 ng/mL, P < 0.01). Much higher hs-CRP concentrations were found in UAP patients (1.58 +/- 2.81 mg/L, P < 0.05) and AMI patients (20.68 +/- 18.98 mg/L, P < 0.01). Cystatin C was positively and significantly correlated with age, hs-CRP, white blood cells (WBC), creatinine, and UA (r > 0, P < 0.05), whereas a significantly negative correlation was observed with HDL-C (r = - 0.227, P < 0.05). These coefficients were clearly high for creatinine (r = + 0.612) and WBC (r = + 0.459). During the 6 month follow-up, 26 patients were found with adverse cardiovascular events and had significantly higher cystatin C levels than the 22 control patients at admission (2356.73 +/- 897.64 ng/mL vs 1469.51 +/- 574.83 ng/mL, P < 0.01). CONCLUSIONS: Cystatin C plays an important role in the development of CAD and PcyC is a strong predictor for risk of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2009) conducted an observational in Acute coronary syndrome (n=160). Plasma cystatin C vs. Healthy subjects / lower cystatin C levels was evaluated on Adverse cardiovascular events (p=<0.01). Patients experiencing adverse cardiovascular events at 6 months had significantly higher admission plasma cystatin C levels compared to controls (2356.73 vs 1469.51 ng/mL, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: